SIRT7-mediated deacetylation of XRCC6 at lysine 591 drives breast cancer progression - Report - MDSpire

SIRT7-mediated deacetylation of XRCC6 at lysine 591 drives breast cancer progression

  • By

  • Jie Yin

  • Jiaxing Liu

  • Meirui He

  • Tang Xiao

  • Wenjuan Xiang

  • Ruxia Sheng

  • Haifang Zhao

  • Xinyue Huang

  • Sheng Xu

  • Yong Zhou

  • Junfeng Liu

  • Ruijuan Heng

  • Xiaoying He

  • Yunxiang Wang

  • Yu Song

  • Pan Qi

  • May 8, 2026

  • 0 min

Share

Clinical Report: The Role of SIRT7 in the Deacetylation of XRCC6 in Breast Cancer

Overview

This study identifies SIRT7 as a specific deacetylase for XRCC6, with reduced acetylation at K591 promoting breast cancer progression. The findings suggest a novel mechanism linking XRCC6 acetylation status to tumor growth and DNA damage repair capacity.

Background

Breast cancer remains a leading malignancy among women, with increasing incidence rates. Understanding the molecular mechanisms underlying breast cancer progression is crucial for developing targeted therapies. This study focuses on the role of acetylation, particularly of XRCC6, in influencing tumor behavior and DNA repair processes.

Data Highlights

No numerical data provided in the article.

Key Findings

  • XRCC6 acetylation at lysine 591 (K591) is significantly reduced in breast cancer tissues.
  • SIRT7 is identified as the specific deacetylase for XRCC6, while EP300 is the acetyltransferase responsible for its acetylation.
  • Downregulation of XRCC6 acetylation enhances its interaction with PARP1, increasing DNA damage repair capacity.
  • In vivo studies show that reduced XRCC6 acetylation promotes tumor growth in xenograft models.
  • Alterations in XRCC6 acetylation may influence breast cancer cell proliferation and invasiveness.

Clinical Implications

The findings highlight the potential of targeting SIRT7 or modulating XRCC6 acetylation as a therapeutic strategy in breast cancer. Understanding the acetylation status of XRCC6 may aid in predicting tumor behavior and patient prognosis.

Conclusion

Summarize the implications of the findings in relation to current breast cancer research.

Related Resources & Content

  1. ASCO Post, 2014 -- Overexpression of Sirt7 Is Associated With Tumorigenesis and Poor Prognosis in Colorectal Cancer
  2. Basic Research in Cardiology, 2012 -- The Promising Functions of Sirtuins in the Context of Heart Failure
  3. Blood Cancer Journal, 2013 -- Alkylating agents promote hyperacetylation of histone H3K18 and enhance the cytotoxic effects of HDAC inhibitors in mantle cell lymphoma
  4. Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline - PubMed
  5. Therapeutic advances and application of PARP inhibitors in breast cancer - PMC
  6. Archives of Toxicology — New Perspectives on the Mechanisms of ATR Activation Induced by Chromatin Configurations
  7. Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline - PubMed
  8. Therapeutic advances and application of PARP inhibitors in breast cancer - PMC
  9. Nuclear porcupine mediates XRCC6/Ku70 S-palmitoylation in the DNA damage response | Experimental Hematology & Oncology | Full Text

Original Source(s)

SIRT7-mediated deacetylation of XRCC6 at lysine 591 drives breast cancer progression

  • by Jie Yin, Jiaxing Liu, Meirui He, Tang Xiao, Wenjuan Xiang, Ruxia Sheng, Haifang Zhao, Xinyue Huang, Sheng Xu, Yong Zhou, Junfeng Liu, Ruijuan Heng, Xiaoying He, Yunxiang Wang, Yu Song, Pan Qi

  • May 8, 2026

Related Content

Vitamin D-related genetic variants as predictive biomarkers for breast cancer in Jordanian women

Financial Hardship and Nonadherence to Lifestyle and Surveillance in Childhood Cancer Survivors

From molecular networks to translational intervention: current progress in the mechanisms of gemcitabine resistance in bladder cancer